NBTXR3 for Advanced Cancers Approved for Clinical Trial in France
For a disease without many options for treatment, every bit of new news is potentially good news. The French Medicine Agency has approved a clinical trial for a novel drug which could potentially be used for sarcoma and other advanced cancers.
Nanobiotix, a clinical stage-nanomedicine company based in Paris, announced that the compound NBTXR3 has received authorization to start clinical trials in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer) at the Institut Curie, a leading French cancer treatment center. NBTXR3 is also in clinical trials for soft tissue sarcoma.
NBTXR3 nanoparticles are designed for direct injection into the cancerous tumor. The product is activated by high-precision radiation therapy (Intensity-modulated radiation therapy or IMRT). The goal is to improve tumor destruction.
The NBTXR3 product is part of Nanobiotix “NanoXray” portfolio of medicines for cancer. According to the World Health Organization (WHO), there will be 15 million new cases of cancer worldwide in the year 2020. Radiotherapy is part of the treatment in about 60% of cancer cases. NanoXray nanoparticles were designed to increase the dose and efficacy of radiotherapy inside the tumor without causing additional damage to healthy dissues.
“The approval from ANSM to start a second clinical trial with NBTXR3 in Head and Neck cancer patients is a major milestone for Nanobiotix,” said Laurent Levy, PhD, CEO of Nanobiotix. “This follows the recent positive intermediate results from the clinical study of NBTXR3 in advanced Soft Tissue Sarcoma patients, which continues the regulatory pathway to market.”
June 17th marked the beginning of Sarcoma Awareness Week in the UK and in Canada. Sarcomas are rare cancers that develop in the muscle, bone, nerve, cartilage, tendons, blood vessels, and fatty/fibrous tissues. Only 1% of all cancer diagnoses in the UK are sarcoma, however, they tend to affect a younger population. About 16% of bone or soft tissue sarcomas are diagnosed in patients less than thirty years of age compared to 2% of other types of cancers.
In addition, the five-year survival rate is low (55%) because this type of cancer is difficult to diagnose and treat.
Agence Nationale de Sécurité du Médicament et des produits de santé